Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 06, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"). As a result of a fund movement on June 30, 2006, the holdings increased from 17,368,515 to 17,396,713 shares. The average price for this movement was $54.96.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Two directors, Dr J P Garnier and Dr M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- Transaction Date: June 30, 2006 (Fund movement); July 05, 2006 (Notification to Company).
- Entity Involved: GlaxoSmithKline US Retirement Savings Plan.
- Share Change: Increase of 28,198 Ordinary Share ADRs (from 17,368,515 to 17,396,713).
- Price: Average price of $54.96 per ADR.
- Directors Affected: Dr J P Garnier and Dr M Slaoui (as potential beneficiaries of the discretionary fund).